Background: The present study has been performed to evaluate the expression of MK-1 in schistosomiasis-associated squamous cell carcinoma of the urinary bladder and to correlate this new marker with the conventional histopathological parameters. Patients and methods: Paraffin sections of 5-µ µm thickness from 81 cases were prepared for hematoxylin and eosin staining and immunohistochemical analysis of MK-1 expression was carried out. Results: Forty-six cases (56.8%) were positive for MK-1 protein expression. Significant correlations between MK-1 expression and tumor grade (p=0.004), schistosoma (p=0.031), DNA ploidy (p=0.001), and tumor recurrence (p<0.001) were observed. MK-1, sex, tumor grade, stage, schistosoma, DNA ploidy, and recurrence were evaluated in relation to outcome. Univariate and multivariate analysis of survival were performed. The overall 5-year survival was 51.85%. In univariate analysis, MK-1 expression, tumor grade, DNA ploidy, and recurrence had a significant impact on the survival of these patients. In a Cox proportional hazards model, recurrence maintained its significant impact on survival. Conclusions: These findings suggest that MK-1 is a prognostic marker for recurrence: 34 (87.2%) of 39 recurrent cases were positive for MK-1 expression. However, only recurrence was an independent prognostic factor in patients with schistosomiasis-associated squamous cell carcinoma of the bladder. (Int J Biol Markers 2006; 21: 170-4)
INTRODUCTION
Primary squamous cell carcinoma (SCC) of the urinary bladder is a relatively rare tumor, comprising 1% to 7% of all bladder cancers in the Western world. It is the most common malignant tumor in men in Egypt, where schistosomiasis is endemic. Non-bilharzial cases are usually associated with chronic infection, vesical calculi, long-term use of indwelling catheters, or bladder diverticula. Almost all SCCs are already advanced and muscle-infiltrating at the time of diagnosis. Transurethral resection, partial cystectomy, radiation therapy, and chemotherapy are not effective. Radical cystectomy and urinary diversion appear to be the treatment of choice in selected cases. In general, the prognosis is poor (1) .
In recent years, monoclonal antibodies (MoAbs) to tumor-associated antigens have become important reagents in the management of cancer (2) . The MoAb FU-MK-1 was established by immunizing mice with cancerous ascites derived from a poorly differentiated adenocarcinoma of the stomach. FU-MK-1 is an IgG1 anti-body reactive with a tumor-associated antigen expressed in most tumor tissues of epithelial origin such as gastric, colon, pancreatic, gallbladder, bile duct, breast, and lung carcinomas (3) . Recent molecular characterization demonstrated that the FU-MK-1 target molecule is a transmembrane glycoprotein with a molecular mass of 40 kDa and is encoded by the GA733-2 gene (4). The GA733-2 antigen is also known as 17-1A antigen, KS1/4 antigen, and Ep-CAM antigen (5) . FU-MK-1 has been suggested to be involved in the differentiation and growth of epithelial cells under normal physiological conditions through its homotypic cell-cell adhesion activity (6) . Because it is overexpressed in most carcinomas, MK-1 has been used as a target for the diagnosis and therapy of cancer (3) . Only a few papers, however, have described the expression and distribution of MK-1 in urological cancers (7) . In the present study, in order to investigate whether MK-1 can be used as a prognostic marker in SCC of the bladder, we examined the expression of MK-1 in 81 cases of bladder SCC associated with bilharziasis.
PATIENTS AND METHODS
All 81 cases were primary SCCs of the urinary bladder diagnosed between January 1990 and December 1995. All data on the clinical management and disease course of the patients were retrieved from the patient records. Formalin-fixed, paraffin-embedded tumor tissues were obtained from the archives of the Urology Department at Mansoura University. The hematoxylin and eosin-stained slides of the tissue samples were reviewed independently, graded according to Mostofi et al's grading scheme (8) , and staged according to the TNM staging system.
Immunohistochemistry
The tissue distribution of the antigen recognized by the monoclonal antibody FU-MK-1 was analyzed by avidin-biotin peroxidase complex techniques. Endogenous peroxidase activity in 4-to 5-µm-thick paraffin sections was blocked by treatment with 0.03% H 2 O 2 in methanol for 20 minutes and 3% H 2 O 2 for 5 minutes. In most paraffin sections, proteolytic digestion was carried out with 0.4% pepsin for 20 minutes at 37°C. The MoAb FU-MK-1 was used as primary antibody (diluted ascites fluid, 1:2000). The slides were preincubated with 10% normal horse serum for 20 minutes to minimize non-specific binding. The slides were sequentially incubated at room temperature with the primary MoAb for 1 hour followed by biotinylated secondary antibody (Vector Laboratories, Burlingame, CA, USA) for 40 minutes and avidin-peroxidase conjugates (Dakopatts, Glostrup, Denmark) for 40 minutes. Diaminobenzidine was used as chromogen. Between incubations the slides were rinsed with phosphate-buffered saline (PBS). The slides were counterstained with hematoxylin. Negative controls were established by replacing the primary antibody with normal serum.
Statistical analysis
The correlations of MoAb FU-MK-1 cytoplasmic staining with tumor stage, grade, and other clinical parameters were analyzed using Fisher's exact test. The Kaplan-Meier procedure was used for univariate survival analysis. Recurrence-free survival (RFS) was defined as the time period (in months) from the date of diagnosis to the date of the first documented clinical recurrence. Overall survival (OS) was defined as the time period from the date of diagnosis to the date of death from any cause. The relationship between the different survival curves was assessed using the log-rank test. Cases with no follow-up data were excluded from the analysis. For multivariate analysis, the Cox regression model was used. All p values reported are two-sided and values of p<0.05 were considered significant. All analyses were performed using SPSS (Statistical Package for the Social Sciences) software (version 10.0).
RESULTS

Results of immunohistochemistry
The distribution of the 81 SCC patients according to immunostaining of the MK-1 protein is shown in Table I . The mean age of the patients was 48.54 years (range: 28-61 years) and there were 58 men and 23 women. Pathologically determined tumor stage was pT2 in 19 cases (23.5%), pT3a in 58 cases (71.6%), and pT3b in 4 cases (4.9%). Tumor grade was GI in 43 cases (53.1%), GII in 16 cases (19.8%), and GIII in 22 cases (27.2%). The correlations between MK-1 expression and each of the tu-
Fig. 1 -Squamous cell carcinoma of the urinary bladder showing brown cytoplasmic staining with MK-1 antibody (avidin-biotin immunoperoxidase, x250)
Fig. 2 -Squamous cell carcinoma of the urinary bladder showing brown cytoplasmic staining with MK-1 antibody (avidin-biotin immunoperoxidase, x400)
mor grades, DNA ploidy, schistosomal infection, and recurrence were significant with p values of 0.004, 0.001, 0.031 and <0.001, respectively.
Thirty-five cases (43.2%) were positive for MK-1. Among the positive cases, brown staining was present in a median of 30% of cells, as shown in Figures 1  and 2 . A positive result for MK-1 was related to histological grade and pathological stage of the tumor, with positivity rates of 38.3% in grade GI, 4.9% in GII, 13.6% in GIII, 13.6% in stage pT2, and 43.2% in pT3a. A statistically significant relationship was demonstrated between MK-1 expression and tumor grade, schistosoma, DNA ploidy, and tumor recurrence. Tumor recurrence was present in 39 cases (48.15%), 34 of which were positive for MK-1 expression.
Prognosis in patients with SCC
Univariate analysis
The Kaplan-Meier estimate of the overall diseasefree survival at 5 years was 51.85% of all cases (81). The following variables: sex, MK-1, tumor grade, pathological stage, schistosoma, DNA ploidy, and recurrence were correlated with survival. The correlation between survival and different tumor parameters is shown in Table II : the survival rate in patients with negative MK-1 expression (94.29%) was better than that in patients with positive MK-1 expression 3 and 4 ).
Multivariate analysis
The 4 factors that had a significant impact on survival in univariate analysis were further evaluated by the Cox regression model. Recurrence remained the only factor that had a statistically significant impact on survival, as shown in Table III .
DISCUSSION
Despite the diversity of clinically available tumor markers, only a few markers are currently used for urological cancer, in particular bladder carcinomas (9) . MK-1 antigen is widely expressed in various human tumors (3); however, only a few reports have described the expression of MK-1 in urological cancer (9) . To our knowledge, this study is the first immunohistochemical study of MK-1 in human SCC of the urinary bladder associated with bilharziasis. We examined the expression of MK-1 in 81 patients. MK-1 expression was demonstrated in 43.2% of the patients; this finding was in agreement with the results of Tomita et al (7) , who reported MK-1 expression in 2 of 5 bladder carcinomas. Some of the MK-1-positive cases exhibited heterogeneity in MK-1 immunoreactivity with regard to the number of stained cells and the intensity of staining. The reason for this heterogeneity is not clear. Immunoreactivity for MK-1 was most frequent in grade I tumors (38.3%), and less in grades II (4.9%) and III (13.6%).
MK-1 is a useful marker for tumor recurrence: 34 (87.2%) of the 39 cases with recurrences were positive for MK-1 expression. In univariate analysis, MK-1 expression, tumor grade, DNA ploidy, and recurrence were significantly correlated with survival, whereas in stepwise regression analysis (multivariate analysis), recurrence remained the only factor that had statistical significance and could be used as a prognostic marker for SCC of the urinary bladder. In conclusion, recurrence could provide the most objective tool for the prediction of patient survival and might help in the choice of the most effective therapy in individual patients. 
